|1.||Bander, Neil H: 8 articles (11/2013 - 11/2003)|
|2.||Vallabhajosula, Shankar: 8 articles (09/2013 - 11/2003)|
|3.||Nanus, David M: 7 articles (09/2013 - 11/2003)|
|4.||Goldsmith, Stanley J: 7 articles (09/2013 - 11/2003)|
|5.||Milowsky, Matthew I: 5 articles (09/2013 - 07/2004)|
|6.||Kostakoglu, Lale: 5 articles (02/2007 - 11/2003)|
|7.||Akhtar, Naveed H: 3 articles (09/2013 - 01/2013)|
|8.||Tagawa, Scott T: 3 articles (09/2013 - 01/2013)|
|9.||Maher, John: 1 article (01/2014)|
|10.||Kampmeier, Florian: 1 article (01/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "In this study a diabody derived from mAb J591 was developed as a single photon emission computed tomography (SPECT) tracer with improved pharmacokinetics for the detection of PSMA expression in prostate cancer. "
03/01/2013 - "Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer."
07/01/2004 - "To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary efficacy of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((90)Y-J591) in patients with androgen-independent prostate cancer (PC). "
07/01/2004 - "Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer."
11/01/2003 - "Patients with progressing hormone independent prostate cancer were entered in 2 phase I dose finding trials with radiolabeled mAb J591. "
09/15/2013 - "Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors."
02/10/2007 - "Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors."
11/01/2013 - "We present the characterization of shear-dependent cancer cell capture in a novel hybrid DEP-immunocapture system consisting of interdigitated electrodes fabricated in a Hele-Shaw flow cell that was functionalized with a monoclonal antibody, J591, which is highly specific to prostate-specific membrane antigen expressing prostate cancer cells. "
10/01/2013 - "We investigated the emerging concept of tumor-targeted synthetic lethality in prostate cancer cells by using the pan-PI3K inhibitor ZSTK474 and the immunotoxin J591PE, a protein chimera between the single-chain variable fragment of the monoclonal antibody J591 against the prostate-specific membrane antigen (PSMA) and the truncated form of the Pseudomonas aeruginosa exotoxin A (PE38QQR). "
|3.||Neoplasm Metastasis (Metastasis)
01/01/2014 - "The monoclonal antibody (mAb) J591 is directed against an extracellular epitope of PSMA and has been shown to efficiently target disseminated disease including metastases in lymph nodes and bone. "
03/01/2006 - "Radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 trials using the radiometals yttrium-90 and lutetium-177 have demonstrated manageable myelotoxicity, no significant nonhematologic toxicity, excellent targeting of soft-tissue and bone metastases, and preliminary efficacy including prostate-specific antigen and measurable disease responses. "
02/01/2013 - "One example is the humanized monoclonal antibody J591 (Hu mAb J591) that was developed primarily for therapeutic purposes but also has interesting imaging characteristics, including the identification of bone metastases in CaP. "
|1.||human glutamate carboxypeptidase II
|2.||Prostate-Specific Antigen (Semenogelase)
|4.||monoclonal antibody J591
|6.||Staphylococcal Protein A (A, Protein)
|8.||poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid)
|10.||Pseudomonas aeruginosa toxA protein
|4.||Drug Therapy (Chemotherapy)